Specialty Generics Face A Maze Of Perverse Incentives In Medicare Part D

Specialty generics haven't gained the kind of traction in Medicare Part D that one would expect. This includes specialty generics such as imatinib mesylate and glatiramer acetate. The current set-up of the Medicare Part D benefit sends the wrong price signals.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive